NICE Threshold Shift, Critical Medicines Act, and MFN Reality Check

Episode 8 — 26 May 2026 NICE confirms new £25,000-£35,000/QALY thresholds while EU reaches provisional agreement on Critical Medicines Act. Trump administration's MFN pricing projects $529 billion savings despite continued industry price increases. Hosted by Marcus and Sara. Outcomes Analytica Podcast — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Transcript

SPEAKER_01 0:00

Nice confirmed the new cost effectiveness thresholds this week. £25,000 to £35,000 per quality, up from the previous £20,000 to £30,000 range, applied to new technology appraisals and those currently underway.

SPEAKER_00 0:15

The timing tells you everything. They're acknowledging inflation reality, but also creating space for higher value technologies. What's interesting is the immediate application to ongoing appraisals. Companies with submissions in the pipeline just got a reprieve they weren't expecting.

SPEAKER_01 0:30

Exactly. But this isn't just about inflation adjustment. It's nice recognizing that the old thresholds were becoming barriers to innovation access. The question is whether this creates sustainable headroom or just shifts the negotiation baseline higher.

SPEAKER_00 0:45

I think it shifts the baseline. Manufacturers will price to the new ceiling, not maintain current pricing with better access odds. We'll see willingness to pay arguments migrate upward. The real test comes with the first few high-value submissions that test the new upper bound.

SPEAKER_01 1:00

Agreed. And it changes the competitive dynamics immediately. Technologies that were borderline at 30,000 pounds now have clear runway. The economic modeling assumptions we've been using for UK submissions need immediate recalibration.

SPEAKER_00 1:14

The provisional agreement on the EU Critical Medicines Act is equally significant for supply chain resilience. This addresses the pharmaceutical supply vulnerabilities we've been tracking since the pandemic.

SPEAKER_01 1:25

True, but the HTA implications are what matter for our audience. Strengthened supply chains could influence availability assumptions in economic models. If security of supply becomes a formal assessment criterion, that's a new value dimension.

SPEAKER_00 1:40

Which brings us to the MFN pricing analysis. The White House projects $529 billion in savings over 10 years from most favored nation drug pricing.

SPEAKER_01 1:49

But here's the disconnect.

SPEAKER_00 2:02

This is where I push back on the savings projections. The $529 billion assumes compliance and static behavior. But if companies with existing agreements are already circumventing through list price increases, the actual savings will be substantially lower.

SPEAKER_01 2:16

You're right to question it. The modeling likely doesn't account for gaming behaviors we're already observing. Companies are finding workarounds before the policy fully implements. The savings estimate becomes aspirational rather than analytical.

SPEAKER_00 2:29

Exactly. It's classic policy modeling that ignores market adaptation. The pharmaceutical industry has decades of experience responding to price controls. MFN won't be different.

SPEAKER_01 2:40

Which makes the real-world evidence acceleration more critical. FDA guidance formalization is driving adoption. 25.2% of supplemental approvals between 2022 to 2024 incorporated RUE, particularly in oncology, infectious diseases, and rheumatology.

SPEAKER_00 2:58

The maturation is clear. What's interesting is that biopharma executives report 85% prioritizing data, digital, and AI platforms for RD, with mature organizations expecting $1 billion cost reductions over five-year periods. That's not incremental improvement.

SPEAKER_01 3:16

No, it's structural change. RWE isn't supplementary anymore. It's becoming core to development strategy. The organizations that master this integration will have significant competitive advantages in both regulatory and HTA submissions.

SPEAKER_00 3:31

The threshold changes, supply chain resilience, pricing policy gaps, and evidence strategy evolution. These aren't separate trends.

SPEAKER_01 3:38

They're converging into a new operating environment. Companies that adapt fastest win.

SPEAKER_00 3:43

Back tomorrow.no.